Avigan® approved for COVID-19 treatment in Malaysia

Avigan® is available in tablet and IV form. It is stable and easy to transport without need for refrigeration, and has a shelf life of ten years.

Global Response Aid (GRA) and Dr. Reddy’s Laboratories will make Avigan® available in Malaysia following a recent decision by the Malaysian Ministry of Health’s Drug Control Authority to approve the anti-viral drug for treatment of patients infected with COVID-19.

The Malaysian Drug Control Authority’s approval of Avigan® is recognition of the urgent need to provide safe and effective treatment solutions to patients diagnosed with COVID-19. It follows recent decisions by regulatory bodies in Indonesia and India to approve Avigan® for treatment of COVID-19 patients.

Avigan® was developed by FujiFilm Toyama Chemical as an influenza anti-viral. In June, FujiFilm signed an agreement with GRA and Dr. Reddy’s for the exclusive global production, distribution and commercialization of the drug. The joint venture has participated in an array of clinical trials of Avigan®, including large studies in the Middle East and five Phase 2 and Phase 3 studies in the United States, Japan, China and the UAE. The drug has shown positive results, reducing fevers and shortening recovery time in patients in the early stages of COVID-19 infection.

Originally developed for influenza, Avigan® or its generic have been used to treat up to 400,000 patients. Avigan® is available in tablet and IV form. It is stable and easy to transport without need for refrigeration, and has a shelf life of ten years.

Mitch Wilson, CEO of GRA, said: “Avigan is increasingly being adopted as a first line defense because it can reduce the likelihood that patients in high-risk categories will ultimately require hospitalization. Approval by Malaysia expands availability and means that Avigan® is now available to treat more than 3 billion people in China, Indonesia, India and Malaysia.

“It has become a vital tool in global and national efforts to stave off a potentially disastrous next wave of COVID-19. We expect further approvals in other countries in the near future and will be announcing multiple manufacturing locations to meet the growing global demand.”

Avigan® was first approved in Japan in 2014 as an influenza anti-viral drug. It has generally been used when there is an outbreak of novel or re-emerging influenza virus infections in which other influenza anti-viral drugs are either not effective or insufficiently effective.

Working with government agencies, local regulatory authorities and prescribers, Avigan® can be provided to patients diagnosed with COVID-19 on a compassionate-use basis for emergency treatment outside of ongoing clinical studies in advance of regulatory approval in a given country.

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email
Editor

Editor

A team of dedicated journalists whose mission is to advocate for ethics and transparency in the maritime industry.

More Stories from Maritime Fairtrade

The best maritime news and insights delivered to you.

Here's what you can expect from us:

  • News & key insights covering the maritime industry
  • Expert analysis and opinions on maritime corruption and more
  • Exclusive interviews